Loading…
Challenging the Biginelli scaffold to surpass the first line antitubercular drugs: Mycobacterium tuberculosis thymidine monophosphate kinase (TMPK mt ) inhibition activity and molecular modelling studies
New Biginelli adducts were rationalised, the introduction of selected anti-tubercular (TB) pharmacophores into the dihydropyrimidine (DHPM) ring of deoxythymidine monophosphate (dTMP), the natural substrate of thymidine monophosphate kinase (TMPK ). Repurposing was one of the design rationale strate...
Saved in:
Published in: | Journal of enzyme inhibition and medicinal chemistry 2024-12, Vol.39 (1), p.2386668 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | New Biginelli adducts were rationalised,
the introduction of selected anti-tubercular (TB) pharmacophores into the dihydropyrimidine (DHPM) ring of deoxythymidine monophosphate (dTMP), the natural substrate of
thymidine monophosphate kinase (TMPK
). Repurposing was one of the design rationale strategies for some selected mimics of the designed compounds. The anti-TB activity was screened against the M
H
Rv strain where
was superior to ethambutol (EMB), and was 9-fold more potent than pyrazinamide (PZA). Additionally, compounds
,
and
elicited higher anti-TB activity than PZA, showing better safety profiles than EMB against RAW 264.7 cells' growth.
TMPK
inhibition assay released compounds
and
as the most potent inhibitors. Docking studies presumed the binding modes and molecular dynamics (MD) simulation revealed the dynamic stability of
TMPK
complex over 100 ns
prediction of the chemo-informatics properties of the most active compounds was conducted. |
---|---|
ISSN: | 1475-6366 1475-6374 1475-6374 |
DOI: | 10.1080/14756366.2024.2386668 |